In the cystic fibrosis (CF) airways, Pseudomonas aeruginosa undergoes diverse physiological changes 13 in response to inflammation, antibiotic pressure, oxidative stress and a dynamic bioavailable nutrient 14 pool. These include loss-of-function mutations that result in reduced virulence, altered metabolism and 15 other phenotypes that are thought to confer a selective advantage for long-term persistence. Recently, 16 clinical isolates of P. aeruginosa that hyperproduce agmatine (decarboxylated arginine) were cultured 17 from individuals with CF. Sputum concentrations of this metabolite were also shown to correlate with 18 disease severity. This raised the question of whether agmatine accumulation might also confer a 19 selective advantage for P. aeruginosa in vivo during chronic colonization of the lung. Here, we screened 20 a library of P. aeruginosa CF clinical isolates and found that ~5% of subjects harbored isolates with an 21 agmatine hyperproducing phenotype. Agmatine accumulation was a direct result of mutations in aguA,
INTRODUCTION
7 Epithelial cell culture model. CF-DHBE bronchial epithelial cells were seeded into 48-well cell culture 138 plates (Costar) coated with bovine collagen at 5x10 4 cells per well in 250µL of BEGM. Cells were 139 incubated at 37°C in humidified air with 5% CO 2 . Media was replaced every 48h until cells were 140 confluent on day 10 post-seeding. Prior to treatment, cell cultures were rinsed twice with 250µL 141 starvation medium (MEM + 0.5% FBS). Cells were then stimulated by adding 10-fold dilutions of 142 agmatine (0.1 -100 µM)(Sigma), 100 ng/mL of LPS from E. coli (Sigma), or agmatine plus LPS in 143 starvation medium to each well. Media-only and media+LPS were used as controls. Treated cells were 144 incubated for an additional 24h, followed by collection of supernatants that were frozen at -80°C for 145 downstream analysis. Supernatants were assayed using the 
151
Agmatine accumulation among P. aeruginosa CF isolates. Given the elevated concentrations of 152 agmatine detected within expectorated sputum and the identification of overproducing strains (26), we 153 first tested our hypothesis that agmatine accumulation (herein referred to as "hyperproduction") is a 154 common phenotype among P. aeruginosa CF isolates. To evaluate its frequency, we used a previously 155 described biosensor assay (31) to quantify agmatine production among a strain library comprising 92 156 CF airway isolates. Isolates were grown to stationary-phase, and supernatants were added to an 157 agmatine-sensitive bioluminescent reporter derivative of P. aeruginosa PA14 (31). Luminescence was 158 then quantified after 3h and normalized to culture density of the reporter strain ( Fig. 2) . Of ninety-two 159 isolates tested, five (5.4%) were found to produce agmatine above the detectable threshold of ~1 µM,
160
including three that were identified previously (26). These concentrations were equal to or above those 161 produced by PA14DaguADagu2Aagu2A', an agmatine hyperproducing lab strain used in the 162 development and validation of the assay (31).
8
Since aguA encodes a deiminase that catalyzes the conversion of agmatine to N-carbamoyl 164 putrescine ( Fig. 1 ), we predicted that mutations at this locus were responsible for agmatine 165 accumulation. To test this, aguA was PCR amplified from each isolate and sequenced. Interestingly,
166
MNPA04, MNPA05, and MNPA06 each harbored an identical 11 base pair deletion in aguA (Fig. S1 ),
167
which may be indicative of patient-to-patient transmission of an agmatine-hyperproducing common 168 ancestor. CHB47-6 and CHB54-11 also harbored 8-bp and 14-bp deletions, respectively, at the 3' end 169 of aguA (Fig. S1 ). Each of these deletions results in a frameshift mutation in the downstream catalytic 170 site of the deiminase. Notably, none of the five hyperproducing isolates contained the alternate 171 agu2ABCA' operon (encoding two additional agmatine deiminases) found in ~20% of P. aeruginosa 172 isolates (32), suggesting that mutations identified in aguA were responsible for the agmatine 173 hyperproduction phenotype. Indeed, when an intact copy of aguA was cloned from strain PA14 and 174 mobilized via allelic exchange into the aguA mutant isolates, agmatine catabolism was restored as 175 determined by the biosensor assay ( Fig. 2 ).
177
Agmatine hyperproduction confers increased tolerance to cationic antibiotics. The isolation of 178 aguA mutants from multiple subjects raised the question of whether agmatine hyperproduction is 179 another example of a loss-of-function phenotype that confers a fitness advantage. For example, does 180 agmatine decrease susceptibility to positively charged antibiotics that destabilize the Gram-negative 181 outer membrane? This question was raised, in part, based on prior reports of exogenously added 182 spermidine and putrescine conferring protection to P. aeruginosa from polymixin B (29, 35) . This was 183 likely due to increased stability of lipopolysaccharide (LPS) via the polycationic charge of the polyamines 184 (29). Though agmatine is a pre-polyamine, it also harbors a dipositive charge, and we hypothesized 185 that its production by the aguA-clinical isolates confers a similar protective effect.
186
Using a microtiter plate-based assay, the minimum inhibitory concentration and IC50 (antibiotic 187 concentration needed to halve the bacterial density at 24h) (36) of three commonly used CF antibiotics 188 with a polycationic charge (colistin, tobramycin, and gentamicin) were determined for MNPA04 and its 189 isogenic aguA+ strain. To ensure that any observed phenotype was specific for agmatine accumulation 190 9 (and not due to a defect in arginine catabolism), we also generated a MNPA04DspeA mutant lacking 191 the arginine decarboxylase (SpeA) required for the first dedicated step of the pathway (see Fig. 1 ).
192
While there was no difference in MIC for any of the compounds tested (data not shown), there was a 193 significant increase in IC50 for each antibiotic versus the agmatine hyperproducer relative to the 194 complemented aguA+ strain (Fig. 3A , Table 2 ). This phenotype was not observed in MNPA04DspeA,
195
suggesting that the observed decreases in antibiotic susceptibility were a direct result of agmatine 196 accumulation.
197
As demonstrated previously for spermidine and putrescine (29, 35) , we predicted that the 198 dipositive charge of agmatine impeded the interaction of cationic antibiotics with the negatively charged 199 bacterial cell surface. To test this, we treated MNPA04, MNPA04+aguA and MNPA04DspeA with three 200 additional CF antibiotics that carry a net neutral or negative charge at physiological pH; ceftazidime, 201 piperacillin, and doxycycline ( Fig. 3B , Table 2 ). As predicted, there were no significant changes in IC50 202 for the neutral or electronegative compounds, supporting the hypothesis that agmatine hyperproduction 203 decreases P. aeruginosa susceptibility to cationic antibiotics due its dipositive charge.
204
Interestingly, resistance phenotypes were strain-dependent; when tobramycin, gentamicin and 205 colistin were tested against other mutant isolates identified in our screen, agmatine conferred increased 206 resistance in just three of five strains (Table S2) . Strain-to-strain variability was not observed for the 207 neutral and negatively charged compounds. Notably, the two isolates for which increased resistance to 208 the aminoglycosides (tobramycin and gentamicin) was not found also had observable phenotypes that 209 may also contribute to antibiotic tolerance -pyomelanin hyperproduction (MNPA06) and mucoidy 210 (CHBPA54-11)( Fig.S3 )(37-39). It is possible that these and/or other phenotypic characteristics affect 211 the agmatine-antibiotic interaction that was observed for MNPA04, MNPA05, and CHB47-6.
212
Nevertheless, the data suggest that deletions in aguA and the consequent accumulation of agmatine 213 may be beneficial for some P. aeruginosa clinical isolates. 
217
However, agmatine has also been shown to reduce macrophage TNF-a and MIP-2 response to 218 bacterial LPS (26). This led to our hypothesis that in a murine acute pneumonia model, the airway 219 inflammatory response to agmatine hyperproducing clinical isolates (aguA-) of P. aeruginosa would 220 also be dampened relative to aguA+ strains. To test this hypothesis, BALB/c mice were challenged 221 intratracheally with either MNPA04 or MNPA04+aguA for 24h, followed by quantification of neutrophil 222 recruitment into the airways. On average, MNPA04 recruited 40% fewer neutrophils than the aguA+ 223 strain (P = 0.002, Figure 4A ). To determine whether this decrease was a result of impaired bacterial 224 growth in vivo, P. aeruginosa colony forming units in BAL were also quantified. Consistent with previous 225 studies (41), a three-log reduction in colony forming units was observed relative to the inoculum after 226 24h, yet there was no significant difference between treatment groups (P=0.48, Figure 4B ). These data 227 suggest that despite a reduction of initial bacterial load, neutrophil recruitment is impaired by P. Fig. 1 ) showed a significant increase in biomass 258 relative to WT. Here we demonstrate that aguA-mutants of P. aeruginosa that hyperproduce agmatine 259 are frequently isolated from the airways of CF patients. Moreover, we present evidence that agmatine 260 accumulation in the extracellular milieu may confer multiple selective advantages for persistence of P. 
264
Mutations in the gene encoding the key quorum-sensing regulator, lasR, are especially common, and 265 lead to defects in the production of key virulence effector compounds (12). Loss-of-function adaptations 266 in gacS, retS, mutS, mucA and ampR (50-53) also increase in prevalence as infections progress and 267 reflect the transition of P. aeruginosa from an acute to chronic infection phenotype. Many of these 268 examples are mutated in only a small fraction of infections (15), which is consistent with the prevalence 269 of aguA mutations (~5%) among our isolate library. While this recovery rate is not nearly as high as QS-12 deficient (lasR), mucoid (mucA) or hypermutator (mutS) phenotypes (12, 54, 55) , parallel evolution of 271 agmatine hyperproduction in P. aeruginosa derived from multiple patients suggests positive selection 272 at the aguA locus. Since our isolate library was derived from de-identified sputum samples for which 273 clinical data were not available, it is unclear whether agmatine hyperproduction is associated with the 274 transition to chronicity. It is also not known whether aguA mutations are selected for by the in vivo 275 microenvironment, or if aguA-environmental isolates are better poised for airway colonization. Future 276 studies aimed at a larger patient cohort with detailed clinical data will help address these questions.
277
The observed decrease in susceptibility of aguA-strains to both aminoglycosides (gentamicin, 278 tobramycin) and polymixins (colistin) suggests that the observed effect is due to a shared characteristic 279 of the antibiotics (e.g. their positive charge). While primary cellular targets differ, the cationic nature of 280 both drug classes is thought to increase outer membrane (OM) permeability to lysozyme and 281 hydrophobic compounds (56, 57) . The initial action of aminoglycosides has been shown to cause 282 disruption of salt-bridges between adjacent LPS molecules, disrupting the normal OM packing order 283 and allowing the compound to then enter the cell and inhibit protein translation (57, 58) . Similarly, 284 polyamines carry a polycationic charge that facilitates binding to LPS. However, owing to their small 285 size, polyamines do not disrupt outer membrane packing or increase OM permeability on their own (58).
286
In fact, the polyamines spermidine and putrescine have been shown to protect Gram-negatives against 287 antimicrobials and oxidative stress, in addition to stabilizing spheroplasts and protecting them against 288 lysis (29, 35, 59, 60) . Given that DspeA mutants (defective in arginine decarboxylation) showed no 289 resistance phenotype and that neutrally charged antibiotics were not affected by aguA mutations, we 290 propose that agmatine also confers resistance to P. aeruginosa due to its dipositive charge.
291
The observed strain-to-strain variability suggesting that agmatine-antibiotic inhibition can be 292 influenced by additional factors was not unexpected. Alginate, for example, has been shown to restrict 293 the diffusion of aminoglycosides (cationic), but not b-lactams (neutral), through mucoid biofilms of P.
294
aeruginosa clinical isolates (61). Elevated concentrations of salts increased aminoglycoside diffusion,
295
suggesting that electrostatic interactions between cationic compounds and extracellular polymers can 296 also impact their efficacy (61, 62) . It remains to be determined whether variations in LPS antigens or the 297 13 production of the extracellular polysaccharides pel and psl that differ in charge and vary among clinical 298 isolates, also impact susceptibility to antibiotic challenge in the presence of agmatine (63,64). Likewise, 299 pyomelanin, an electronegative pigment that is overproduced due to mutations in hmgA, exhibits humic-300 type properties that allows for chelation of soluble cations (65). It is possible that (in the case of 301 MNPA06) its polyanionic charge may impact cell surface interactions with polyamines and antibiotics.
302
We are currently using whole genome sequencing and phenotypic assays of the aguA-mutants to 303 understand how these and other phenotypes (including biofilm formation) influence the protective 304 effects of agmatine for P. aeruginosa.
305
CF airway disease is characterized by chronic, neutrophil-dominated inflammation in response 306 to bacterial infection. However, P. aeruginosa can also use numerous strategies to evade detection and 307 eradication by the immune system. These include formation of biofilms that prevent phagocytic 308 clearance, altered expression of PAMPs such that detection by host immune receptors and downstream 309 signaling is minimized, and direct interference with host signaling through effector molecules (66-67).
310
In the case of agmatine, impaired recruitment of neutrophils is an example of the latter. More 311 specifically, we favor the interpretation that the dipositive charge of agmatine prevents binding of LPS 312 by LPS-binding protein (LBP) and the downstream production of pro-inflammatory cytokines (e.g. IL-8).
313
These data are consistent with previous reports of diminished MIP-2 production in murine peritoneal 314 macrophages in response to LPS in the presence of agmatine (26). Given that cationic antimicrobial 315 peptides have been shown to block LPS-LBP interactions and macrophage cytokine production (68), 316 our data support a similar mechanism for agmatine.
317
It has been shown that agmatine is capable of both immune activation and inhibition depending 318 on the presence and dose of co-stimulatory molecules (26). This dichotomy may explain, at least in 319 part, contrasting phenotypes between the lung adapted isolate MN004 reported here, and those found 320 for the virulent burn wound isolate PA14 (26) which is known to produce an array of immunostimulatory 321 exoproducts (e.g. pyocyanin). Similarily, the acute pneumonia model used here revealed no difference 322 in bacterial load between aguA-and aguA+ variants of MN004, whereas an agmatine hyperproducing 323 mutant of PA14 showed a significant in vivo growth defect relative to the wildtype (26). These strain-to-strain variations, similar to those observed for antibiotic tolerance, underscore the potential 325 combinatorial effect of multiple phenotypes on agmatine-mediated interactions of P. aeruginosa with its 326 growth environment.
327
Despite these variations, agmatine hyperproduction has potential consequences for long-term 
